Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report released on Thursday. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners dropped their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

AWH stock opened at $0.86 on Thursday. Aspira Women’s Health has a 52 week low of $0.74 and a 52 week high of $5.65. The firm’s 50-day moving average is $0.87 and its two-hundred day moving average is $1.49.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The company had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same quarter last year, the firm posted ($0.28) earnings per share. Equities analysts anticipate that Aspira Women’s Health will post -1.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. Institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.